Larimar Therapeutics, Inc.
LRMR
$4.36
$0.092.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -32.78M | -29.61M | -62.50M | -47.71M | -26.18M |
| Total Depreciation and Amortization | 62.00K | 64.00K | 87.00K | 88.00K | 87.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.79M | 1.81M | 1.32M | 1.39M | 1.29M |
| Change in Net Operating Assets | -13.10M | -16.88M | 22.56M | 17.48M | 5.42M |
| Cash from Operations | -44.03M | -44.61M | -38.53M | -28.75M | -19.38M |
| Capital Expenditure | -130.00K | -- | 0.00 | -23.00K | -19.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -40.78M | 29.00M | 34.00M | 33.04M | 18.86M |
| Cash from Investing | -40.91M | 29.00M | 34.00M | 33.02M | 18.84M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 108.12M | -- | 65.29M | -- |
| Repurchase of Common Stock | -435.00K | -- | -201.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -435.00K | 108.12M | -201.00K | 65.29M | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -85.38M | 92.50M | -4.73M | 69.55M | -539.00K |